Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirabegron - Astellas Pharma

Drug Profile

Mirabegron - Astellas Pharma

Alternative Names: Betanis; Betmiga; Betmiga PR; Myrbetriq; YM-178

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Johns Hopkins University
  • Class Acetamides; Antihyperglycaemics; Erectile dysfunction therapies; Ethanolamines; Small molecules; Thiazoles; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • Phase III Interstitial cystitis
  • Phase I/II Erectile dysfunction
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 03 Oct 2019 Astellas Pharma and Philadelphia Urology Associates terminates a phase III pilot trial in Interstitial cystitis due to low patient enrolment in USA (PO) (NCT02787083)
  • 06 May 2019 Astellas Pharma completes the phase III Crocodile trial for Overactive bladder (In adolescents, In children) in Belgium, Denmark, Lithuania, Australia, Colombia, Jordan, South Korea, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan, Latvia, Croatia, Israel and Turkey (PO) (NCT02751931)
  • 05 Feb 2019 Astellas Pharma and Clinical Research Support Center Kyushu completes the phase II CONTACT trial for Overactive bladder (associated with benign prostatic hyperplasia) in Japan (PO) (UMIN000025282)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top